Epidemiology of invasive meningococcal disease in Cyprus 2004 to 2018.
Adolescent
Adult
Age Distribution
Aged
Aged, 80 and over
Child
Child, Preschool
Cyprus
/ epidemiology
Disease Outbreaks
/ statistics & numerical data
Female
Humans
Immunization Programs
Incidence
Infant
Infant, Newborn
Male
Meningococcal Infections
/ diagnosis
Meningococcal Vaccines
/ administration & dosage
Middle Aged
Mortality
/ trends
Neisseria meningitidis
/ classification
Retrospective Studies
Risk Assessment
Risk Factors
Serogroup
Sex Distribution
Young Adult
Cyprus
Epidemiology
Invasive meningococcal disease (IMD)
Neisseria meningitidis
immunisation programmes
risk factors
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
29
12
2020
Statut:
ppublish
Résumé
BackgroundDespite progress in the management of invasive meningococcal disease (IMD) it causes significant mortality and sequelae.AimThis study aims to describe the epidemiology and clinical characteristics of IMD in Cyprus and discuss the current immunisation programmes.MethodsThis is a retrospective study of all cases of IMD notified to the Ministry of Health between 2004 and 2018. Demographic, epidemiological, clinical and microbiological data were collected when a new case was notified. Risk factors associated with mortality were investigated using univariable logistic regression.Results54 cases of IMD were recorded, an overall incidence of 0.4 cases per 100,000 population. The incidence rate was highest among infants (7.2/100,000) and adolescents (1.4/100,000). Case fatality rate was 10.4%. Serogroup B accounted for 24 of 40 cases caused by known serogroup. Serogroups W and Y comprised nine cases and were responsible for most fatal cases. Serogroup C was the cause in only four cases. There was an increase in the odds of death with increasing age, while the presence of meningitis in the clinical picture was found to be associated with lower odds of death.ConclusionDespite the low incidence of IMD in Cyprus, it remains an important cause of morbidity and mortality. Serogroup B is the most frequent serogroup, while incidence of serogroups W and Y is rising. Monitoring new cases and yearly evaluation of the immunisation programmes by the National Immunization Technical Advisory Group (NITAG) is essential for successful control of the disease.
Identifiants
pubmed: 32734853
doi: 10.2807/1560-7917.ES.2020.25.30.1900534
pmc: PMC7393851
doi:
Substances chimiques
Meningococcal Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Infect Dis. 2015 Apr 15;60(8):e27-35
pubmed: 25605282
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3140-5
pubmed: 9501229
Epidemiol Infect. 1987 Dec;99(3):591-601
pubmed: 3123263
Arch Dis Child. 2016 Dec;101(12):1125-1129
pubmed: 27566800
Microbiology. 2003 Jul;149(Pt 7):1849-1858
pubmed: 12855736
Clin Vaccine Immunol. 2010 May;17(5):840-7
pubmed: 20219881
FEMS Microbiol Rev. 2007 Jan;31(1):27-36
pubmed: 17168995
Lancet. 2004 Jul 24-30;364(9431):365-7
pubmed: 15276396
FEMS Immunol Med Microbiol. 2008 Jul;53(2):178-82
pubmed: 18623625
Clin Infect Dis. 2009 Mar 1;48(5):587-94
pubmed: 19191644
J Pediatric Infect Dis Soc. 2012 Mar;1(1):64-73
pubmed: 23687573
Clin Infect Dis. 2010 Jan 15;50(2):184-91
pubmed: 20001736
Pediatrics. 2015 Feb;135(2):e305-11
pubmed: 25583921
Hum Vaccin Immunother. 2014;10(6):1725-8
pubmed: 24608912
Stat Med. 2002 Aug 30;21(16):2409-19
pubmed: 12210625
Lancet. 2016 Dec 3;388(10061):2775-2782
pubmed: 28100432
Infect Immun. 2009 Sep;77(9):3588-95
pubmed: 19528219
Vaccine. 2012 May 30;30 Suppl 2:B3-9
pubmed: 22607896
Clin Microbiol Infect. 2005 May;11(5):386-90
pubmed: 15819865
Emerg Infect Dis. 2004 Apr;10(4):674-8
pubmed: 15200858
Pediatr Infect Dis J. 1996 Nov;15(11):967-78; quiz 979
pubmed: 8933544
Proc R Soc Med. 1939 Oct;32(12):1551-72
pubmed: 19992142
PLoS One. 2014 Sep 29;9(9):e107486
pubmed: 25265409
Diagn Microbiol Infect Dis. 2011 Aug;70(4):427-34
pubmed: 21658876
Eur J Epidemiol. 2000;16(11):1051-6
pubmed: 11421475
Euro Surveill. 2019 Apr;24(14):
pubmed: 30968827
Vaccine. 2017 Apr 11;35(16):2034-2041
pubmed: 28314560
Vaccine. 2012 May 21;30(24):3710-6
pubmed: 22429756
J Clin Microbiol. 2016 Sep;54(9):2251-61
pubmed: 27335149
Vaccine. 2009 Jun 24;27 Suppl 2:B51-63
pubmed: 19477562
MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28
pubmed: 23515099
Lancet. 2002 May 25;359(9320):1829-31
pubmed: 12044380